Discovery of diagnostic markers by metabolomics
update：2020-06-16
Features
Losing cholesterol homeostasis with inborn errors of metabolisms or hepatobiliary diseases makes a change to in vivo cholesterol metabolism profile and causes the emergence of increased metabolites as conjugates in blood and urine. We have developed an LC/ESI-MS/MS method using fragment patterns characteristic of conjugation types for group-specific and comprehensive analysis of conjugated cholesterol metabolites. This method can contribute for an efficient discovery of diagnostic marker candidates toward various diseases.Targeted Application(s)/Industry
After availability verification of candidates as diagnostic markers, it will be required screening tests. We have potential to collaborate with company for development of bioassay systems using antibodies or enzymes.Researchers
Keywords
Related Information
Focused metabolomics using liquid chromatography/electrospray ionization tandem mass spectrometry for analysis of urinary conjugated cholesterol metabolites from patients with Niemann–Pick disease type C and 3β-hydroxysteroid dehydrogenase deficiency,
Ann. Clin. Biochem., in press.
2.Masamitsu Maekawa, Yasushi Misawa, Ayako Sotoura, Hiroaki Yamaguchi, Masami Togawa, Kousaku Ohno, Hiroshi Nittono, Genta Kakiyama, Takashi Iida, Alan F. Hofmann, Junichi Goto, Miki Shimada, Nariyasu Mano,
LC/ESI-MS/MS analysis of urinary 3β-sulfooxy-7β-N-acetylglucosaminyl-5-cholen-24-oic acid and its amides: New biomarkers for the detection of Niemann–Pick type C disease,
Steroids, 78, 967-972 (2013).
Prev
List
Next